Miriam Molina-Arcas

13PUBLICATIONS
121CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 08, 2026
KRAS Inhibitor Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones.

|Jun 01, 2026
Sensitizing Lung Cancer to Immunotherapy with a RAS(ON) Inhibitor Doublet.

|Jan 14, 2026
Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Kevin W Ng, Jesse Boumelha, Katey S S Enfield

|Oct 09, 2025
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2.

Joseph E Klebba, Nilotpal Roy, Steffen M Bernard

|Nov 01, 2024
Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.

Megan Cole, Panayiotis Anastasiou, Claudia Lee

|Sep 25, 2024
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

Panayiotis Anastasiou, Christopher Moore, Sareena Rana

Pageof 3

Frequent Collaborators

13 joint publications

Julian Downward

8 joint publications

Christopher Moore

4 joint publications

Charles Swanton

4 joint publications

Sophie de Carné Trécesson